HilleVax, Inc. (HLVX) Investigation: Bronstein, Gewirtz &

NEW YORK, July 14, 2024 (GLOBE NEWSWIRE) — Attorney Advertising – Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of HilleVax, Inc. (“HilleVax” or “the Company”) (NASDAQ: HLVX). Investors who purchased HilleVax securities are encouraged to obtain additional information and assist in the investigation by visiting the Company’s website: bgandg.com/HLVX.

Examination details

On July 8, 2024, Fierce Biotech published an article stating, “HilleVax stock plunged after the biotech’s only clinical-stage vaccine candidate failed a Phase 2b trial for norovirus-related acute gastroenteritis (AGE).” The article continues, “The virus-like particle-based vaccine, called HIL-214, missed all primary and secondary endpoints of the NEST-IN1 trial of more than 2,800 infants around five months of age in the U.S. and Latin America.” Following this news, shareholders took a hit.

What’s next?

If you are aware of facts related to this investigation, or if you purchased HilleVax securities, you may assist this investigation by visiting the company’s website: bgandg.com/HLVX. You may also contact Peretz Bronstein or his account representative, Nathan Miller of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.

There are no costs for you

We represent investors in class action lawsuits on a contingency basis, meaning we ask the court to reimburse us for our expenses and attorney fees (usually a percentage of the total award) only if we win.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized law firm representing investors in securities fraud class action lawsuits and shareholder actions involving derivatives trading. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Past results do not guarantee similar results.

Contact

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [email protected]